- Recommended for you!
- Preclinical Safety Assessment and Drug Safety Testing.
Google Scholar. Jean-Pierre Valentin. Cite Citation. Permissions Icon Permissions. Abstract Current gaps in drug safety sciences can result from the inability 1 to identify hazard across multiple target organs, 2 to predict and risk assess with certainty against drug safety liabilities for the major target organs, 3 to optimally manage and mitigate against drug safety liabilities, and 4 to apply principles of governance on the generation, integration, and use of experimental data. Figure 1. Open in new tab Download slide.
Figure 2. Figure 3. In silico tools can offer some physicochemical properties in model build Edginton, Concentration gradients in exposure maintenance may become important factors in chronic exposure or delayed toxicodynamic events Soldatow et al. No temporal events ie, acute responses are perturbations of the biological system, but chronic assessment of risk requires maintaining exposure. Most AOPs are descriptive and in vitro tests are typically short term 24—72 h tests. Models can be adapted to study effects of drug toxicities up to 2—4 weeks. No single in vitro model will recapitulate a complete AOP pathway.
Mitochondrial depletion independent of cell death Kamalian et al. Toxicology species and AOPs are not relevant to human. KE can relate biology between species and animals.
Drug Safety Evaluation, 3rd Edition
Examples of reverse translation can be applied to probe ADRs. A network-based approach to understanding drug toxicity and species may help explain mechanisms of toxicity and predict distinct toxicity phenotypes Sutherland et al. Limited application eg, Poor understanding between cellular events and target organ AO. Insufficient mechanistic knowledge. Safety testing typically focuses on a few endpoints and not mechanisms. A signal KE test that typically unifies a particular clinical outcome can support hazard identification for a particular ADR.
Studies to investigate hypersensitivity reactions can be studied and response determined in in vitro tests Azoury et al. Limited direct applicability to drug safety assessment. Species differences prevent building of AOPs for interspecies comparative assessment.
Limited amount of usable interspecies data and information. Patterns of co-regulated genes can Potentially be studied in lieu of specific genes where there are suspected orthologue differences. Coexpression when conserved have higher functional significance Bergmann et al. Need to develop AOPs and prioritize key investment areas to generate alternatives to safety testing.
To adopt AOPs and employ during drug discovery and development. The emerging role of in vitro electrophysiological methods in CNS safety pharmacology. Search ADS. Key challenges and opportunities associated with the use of in vitro models to detect human DILI: Integrated risk assessment and mitigation plans.
Identification of T-cell epitopes from benzylpenicillin conjugated to human serum albumin and implication in penicillin allergy. An analysis of the use of dogs in predicting human toxicology and drug safety. Predicting human drug toxicity and safety via animal tests: Can any one species predict drug toxicity in any other, and do monkeys help?
Microfluidic cell culture platforms to capture hepatic physiology and complex cellular interactions. Strategies to improve the regulatory assessment of developmental neurotoxicity DNT using in vitro methods. Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: A multicenter study. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
Reducing safety-related drug attrition: The use of in vitro pharmacological profiling. Adverse outcome pathways can drive non-animal approaches for safety assessment. Yale School of Public Health Symposium on tissue imaging mass spectrometry: illuminating phenotypic heterogeneity and drug disposition at the molecular level. A decade of toxicogenomic research and its contribution to toxicological science.
A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans.
Google Preview. In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: an industry survey. Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. Pharmacological validation of a semi-automated in vitro hippocampal brain slice assay for assessment of seizure liability.
Table of contents
Detection of primary T cell responses to drugs and chemicals in HLA-typed volunteers: Implications for the prediction of drug immunogenicity. Tissue influx of neutrophils and monocytes is delayed during development of trovafloxacin-induced tumor necrosis factor-dependent liver injury in mice. Development and use of in vitro alternatives to animal testing by the pharmaceutical industry Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how. Part II: Screening strategies. A human disease model of drug toxicity—induced pulmonary edema in a lung-on-a-chip microdevice.
The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death.
Toxicity testing in the 21st century: implications for human health risk assessment. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates.
How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?
Drug Safety Evaluation | Wiley Online Books
Recognizing drug-induced liver injury: Current problems, possible solutions. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Potential functional and pathological side effects related to off-target pharmacological activity. Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials.
Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database. Use of animal models of human disease for nonclinical safety assessment of novel pharmaceuticals. Affinity purification-mass spectrometry and network analysis to understand protein-protein interactions.
Microphysiological 3D model of amyotrophic lateral sclerosis ALS from human iPS-derived muscle cells and optogenetic motor neurons. Chemical or drug hypersensitivity: Is the immune system clearing the danger? Secondary pharmacology data to assess potential off-target activity of new drugs: A regulatory perspective. Advances in molecular toxicology—towards understanding idiosyncratic drug toxicity. Can non-clinical repolarization assays predict the results of clinical thorough QT studies?